Anthem Inc.

IRA’s restructuring of cost-sharing in the catastrophic phase could force plans to restrict utilization

Documents raise questions about McKinsey’s work for FDA, life sciences clients

Following last month’s 4-0 vote by the FTC to challenge Illumina’s pending $7.1 billion acquisition of Grail, the company announced that it filed an action in the General Court of

Chances for safer opioids have nosedived with recent FDA and payer track records

How ICER is becoming the U.S.’s de facto HTA agency